Eton Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Eton Pharmaceuticals, Inc. (ETON) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $333.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-19
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $218.85K.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was -$152.85K, a 527158.62% decline year-over-year.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was -$29.00.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $29.00.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $333.00K, a 52.05% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $219.00K.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $188.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $333.00K 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $218.85K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $66.00K derived: sum of 2 quarters · filed 2026-03-19 | $219.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$152.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $153.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $153.00K 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | -$29.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 10-K · filed 2026-03-19 | |
| 2023-09-30 | $29.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $29.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $188.00K 10-K · filed 2025-03-18 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $195.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |